Esperion Therapeutics Inc. (ESPR) is scheduled to have an End-of-Phase 2 meeting with the FDA in the first half of August to discuss the planned phase 3 program for ETC-1002 for the treatment of patients with hyperlipidemia and mixed dyslipidemia.
Forex – financial instrument.Forex news
Esperion Therapeutics Inc. (ESPR) is scheduled to have an End-of-Phase 2 meeting with the FDA in the first half of August to discuss the planned phase 3 program for ETC-1002 for the treatment of patients with hyperlipidemia and mixed dyslipidemia.